Effectiveness of Fluticasone Furoate/Vilanterol in COPD in clinical practiceCitation formats

  • External authors:
  • David Leather
  • Nawar Diar Bakerly
  • John New
  • Martin Gibson
  • Sheila Mccorkindale
  • Susan Collier
  • Jodie Crawford
  • Lucy Frith
  • Catherine Harvey
  • Henrik Svedsater
  • Ashley Woodcock

Standard

Effectiveness of Fluticasone Furoate/Vilanterol in COPD in clinical practice. / Vestbo, Jorgen; Leather, David; Bakerly, Nawar Diar; New, John; Gibson, Martin; Mccorkindale, Sheila; Collier, Susan; Crawford, Jodie; Frith, Lucy; Harvey, Catherine; Svedsater, Henrik; Woodcock, Ashley.

In: The New England Journal of Medicine, 29.09.2016, p. 1253-1260.

Research output: Contribution to journalArticle

Harvard

Vestbo, J, Leather, D, Bakerly, ND, New, J, Gibson, M, Mccorkindale, S, Collier, S, Crawford, J, Frith, L, Harvey, C, Svedsater, H & Woodcock, A 2016, 'Effectiveness of Fluticasone Furoate/Vilanterol in COPD in clinical practice', The New England Journal of Medicine, pp. 1253-1260. https://doi.org/10.1056/NEJMoa1608033

APA

Vestbo, J., Leather, D., Bakerly, N. D., New, J., Gibson, M., Mccorkindale, S., ... Woodcock, A. (2016). Effectiveness of Fluticasone Furoate/Vilanterol in COPD in clinical practice. The New England Journal of Medicine, 1253-1260. https://doi.org/10.1056/NEJMoa1608033

Vancouver

Vestbo J, Leather D, Bakerly ND, New J, Gibson M, Mccorkindale S et al. Effectiveness of Fluticasone Furoate/Vilanterol in COPD in clinical practice. The New England Journal of Medicine. 2016 Sep 29;1253-1260. https://doi.org/10.1056/NEJMoa1608033

Author

Vestbo, Jorgen ; Leather, David ; Bakerly, Nawar Diar ; New, John ; Gibson, Martin ; Mccorkindale, Sheila ; Collier, Susan ; Crawford, Jodie ; Frith, Lucy ; Harvey, Catherine ; Svedsater, Henrik ; Woodcock, Ashley. / Effectiveness of Fluticasone Furoate/Vilanterol in COPD in clinical practice. In: The New England Journal of Medicine. 2016 ; pp. 1253-1260.

Bibtex

@article{ed5ae38b0e7d498c97f9247a0f76b841,
title = "Effectiveness of Fluticasone Furoate/Vilanterol in COPD in clinical practice",
abstract = "Background. Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials on patient groups selected on restricted entry criteria. There is a need for randomized trials closer to usual clinical practice.Methods. In a randomized, controlled effectiveness trial, 2,799 patients with a general practitioner’s diagnosis of COPD were initiated on once-daily inhaled combination of 100 μg fluticasone furoate and 25 μg vilanterol (FF/VI) or usual care. The primary outcome was moderate-severe exacerbations in patients who had an exacerbation within 1 year before the study. Secondary outcomes were primary and secondary care contacts, modification to initial study COPD treatment, and time to exacerbations in patients who had an exacerbation within 3 years before the study. Results. Compared with usual care, the rate of moderate-severe exacerbations was significantly reduced by FF/VI therapy, percent reduction 8.4{\%} (95{\%} confidence interval [CI] 1.1 to 15.2{\%}, p=0.025). There was no difference in annual rate of COPD-related contacts to primary or secondary care. There was no difference in time to first moderate-severe exacerbation and time to first severe exacerbation between the FF/VI group vs. the usual care group. There were no excess serious adverse events of pneumonia in the FF/VI group. Other serious adverse events were similar between treatment arms.Conclusion. In patients with a general practitioner’s diagnosis of COPD and a history of exacerbations, a simple once-daily treatment regimen of combined fluticasone furoate and vilanterol reduced exacerbations without increasing risk of serious adverse events compared to usual care.The study is registered on clinicaltrials.gov as NCT01551758.",
author = "Jorgen Vestbo and David Leather and Bakerly, {Nawar Diar} and John New and Martin Gibson and Sheila Mccorkindale and Susan Collier and Jodie Crawford and Lucy Frith and Catherine Harvey and Henrik Svedsater and Ashley Woodcock",
year = "2016",
month = "9",
day = "29",
doi = "10.1056/NEJMoa1608033",
language = "English",
pages = "1253--1260",
journal = "The New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",

}

RIS

TY - JOUR

T1 - Effectiveness of Fluticasone Furoate/Vilanterol in COPD in clinical practice

AU - Vestbo, Jorgen

AU - Leather, David

AU - Bakerly, Nawar Diar

AU - New, John

AU - Gibson, Martin

AU - Mccorkindale, Sheila

AU - Collier, Susan

AU - Crawford, Jodie

AU - Frith, Lucy

AU - Harvey, Catherine

AU - Svedsater, Henrik

AU - Woodcock, Ashley

PY - 2016/9/29

Y1 - 2016/9/29

N2 - Background. Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials on patient groups selected on restricted entry criteria. There is a need for randomized trials closer to usual clinical practice.Methods. In a randomized, controlled effectiveness trial, 2,799 patients with a general practitioner’s diagnosis of COPD were initiated on once-daily inhaled combination of 100 μg fluticasone furoate and 25 μg vilanterol (FF/VI) or usual care. The primary outcome was moderate-severe exacerbations in patients who had an exacerbation within 1 year before the study. Secondary outcomes were primary and secondary care contacts, modification to initial study COPD treatment, and time to exacerbations in patients who had an exacerbation within 3 years before the study. Results. Compared with usual care, the rate of moderate-severe exacerbations was significantly reduced by FF/VI therapy, percent reduction 8.4% (95% confidence interval [CI] 1.1 to 15.2%, p=0.025). There was no difference in annual rate of COPD-related contacts to primary or secondary care. There was no difference in time to first moderate-severe exacerbation and time to first severe exacerbation between the FF/VI group vs. the usual care group. There were no excess serious adverse events of pneumonia in the FF/VI group. Other serious adverse events were similar between treatment arms.Conclusion. In patients with a general practitioner’s diagnosis of COPD and a history of exacerbations, a simple once-daily treatment regimen of combined fluticasone furoate and vilanterol reduced exacerbations without increasing risk of serious adverse events compared to usual care.The study is registered on clinicaltrials.gov as NCT01551758.

AB - Background. Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials on patient groups selected on restricted entry criteria. There is a need for randomized trials closer to usual clinical practice.Methods. In a randomized, controlled effectiveness trial, 2,799 patients with a general practitioner’s diagnosis of COPD were initiated on once-daily inhaled combination of 100 μg fluticasone furoate and 25 μg vilanterol (FF/VI) or usual care. The primary outcome was moderate-severe exacerbations in patients who had an exacerbation within 1 year before the study. Secondary outcomes were primary and secondary care contacts, modification to initial study COPD treatment, and time to exacerbations in patients who had an exacerbation within 3 years before the study. Results. Compared with usual care, the rate of moderate-severe exacerbations was significantly reduced by FF/VI therapy, percent reduction 8.4% (95% confidence interval [CI] 1.1 to 15.2%, p=0.025). There was no difference in annual rate of COPD-related contacts to primary or secondary care. There was no difference in time to first moderate-severe exacerbation and time to first severe exacerbation between the FF/VI group vs. the usual care group. There were no excess serious adverse events of pneumonia in the FF/VI group. Other serious adverse events were similar between treatment arms.Conclusion. In patients with a general practitioner’s diagnosis of COPD and a history of exacerbations, a simple once-daily treatment regimen of combined fluticasone furoate and vilanterol reduced exacerbations without increasing risk of serious adverse events compared to usual care.The study is registered on clinicaltrials.gov as NCT01551758.

U2 - 10.1056/NEJMoa1608033

DO - 10.1056/NEJMoa1608033

M3 - Article

SP - 1253

EP - 1260

JO - The New England Journal of Medicine

T2 - The New England Journal of Medicine

JF - The New England Journal of Medicine

SN - 1533-4406

ER -